Qyuns Therapeutics buys back 57,200 H-shares; treasury stock climbs to 2.94 million

Bulletin Express06-02

On 2 June 2026, Qyuns Therapeutics Co., Ltd. executed an on-exchange repurchase of 57,200 H-shares, according to the Next Day Disclosure Return filed with the Hong Kong Stock Exchange.

• Transaction details – Price range: HKD 15.96 to HKD 16.70 per share – Volume-weighted average price (Section I): HKD 16.51 per share – Aggregate consideration: HKD 0.94 million

• Impact on share capital – Outstanding issued shares (excluding treasury) fell from 224.19 million to 224.13 million, a reduction of 0.0255%. – Treasury share balance increased from 2.88 million to 2.94 million. – Total issued shares (including treasury) remained unchanged at 227.07 million.

• Repurchase mandate utilisation – Shareholders approved a mandate on 29 May 2026 authorising repurchases of up to 22.44 million shares. – Cumulative repurchases under the mandate now stand at 231,600 shares, representing 0.1032% of the company’s issued shares on the mandate date. – A 30-day moratorium on new share issues or treasury share sales runs until 2 July 2026.

The company confirmed that all repurchases were conducted in accordance with Main Board Rule 10.06 and that no material changes have been made to the explanatory statement dated 8 May 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1123283149?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-02 20:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123283149","market":"hk","top_or_hot":-1,"title":"Qyuns Therapeutics buys back 57,200 H-shares; treasury stock climbs to 2.94 million","media":"Bulletin Express","content":"<p>On 2 June 2026, Qyuns Therapeutics Co., Ltd. executed an on-exchange repurchase of 57,200 H-shares, according to the Next Day Disclosure Return filed with the Hong Kong Stock Exchange.</p>\n<p>• Transaction details  \n– Price range: HKD 15.96 to HKD 16.70 per share  \n– Volume-weighted average price (Section I): HKD 16.51 per share  \n– Aggregate consideration: HKD 0.94 million</p>\n<p>• Impact on share capital  \n– Outstanding issued shares (excluding treasury) fell from 224.19 million to 224.13 million, a reduction of 0.0255%.  \n– Treasury share balance increased from 2.88 million to 2.94 million.  \n– Total issued shares (including treasury) remained unchanged at 227.07 million.</p>\n<p>• Repurchase mandate utilisation  \n– Shareholders approved a mandate on 29 May 2026 authorising repurchases of up to 22.44 million shares.  \n– Cumulative repurchases under the mandate now stand at 231,600 shares, representing 0.1032% of the company’s issued shares on the mandate date.  \n– A 30-day moratorium on new share issues or treasury share sales runs until 2 July 2026.</p>\n<p>The company confirmed that all repurchases were conducted in accordance with Main Board Rule 10.06 and that no material changes have been made to the explanatory statement dated 8 May 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Qyuns Therapeutics buys back 57,200 H-shares; treasury stock climbs to 2.94 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQyuns Therapeutics buys back 57,200 H-shares; treasury stock climbs to 2.94 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-02 20:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On 2 June 2026, Qyuns Therapeutics Co., Ltd. executed an on-exchange repurchase of 57,200 H-shares, according to the Next Day Disclosure Return filed with the Hong Kong Stock Exchange.</p>\n<p>• Transaction details  \n– Price range: HKD 15.96 to HKD 16.70 per share  \n– Volume-weighted average price (Section I): HKD 16.51 per share  \n– Aggregate consideration: HKD 0.94 million</p>\n<p>• Impact on share capital  \n– Outstanding issued shares (excluding treasury) fell from 224.19 million to 224.13 million, a reduction of 0.0255%.  \n– Treasury share balance increased from 2.88 million to 2.94 million.  \n– Total issued shares (including treasury) remained unchanged at 227.07 million.</p>\n<p>• Repurchase mandate utilisation  \n– Shareholders approved a mandate on 29 May 2026 authorising repurchases of up to 22.44 million shares.  \n– Cumulative repurchases under the mandate now stand at 231,600 shares, representing 0.1032% of the company’s issued shares on the mandate date.  \n– A 30-day moratorium on new share issues or treasury share sales runs until 2 July 2026.</p>\n<p>The company confirmed that all repurchases were conducted in accordance with Main Board Rule 10.06 and that no material changes have been made to the explanatory statement dated 8 May 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02509","symbol_name":"荃信生物-B","start_time":0,"source_url":"","article_id":"1123283149","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123283149","pubTimestamp":1780404234,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"On 2 June 2026, Qyuns Therapeutics Co., Ltd. executed an on-exchange repurchase of 57,200 H-shares, according to the Next Day Disclosure Return filed with the Hong Kong Stock Exchange. • Transaction...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02509":"荃信生物-B"},"translate_title":"Qyuns Therapeutics回购57,200股H股；库存股攀升至294万股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02509":1},"content_text":"On 2 June 2026, Qyuns Therapeutics Co., Ltd. executed an on-exchange repurchase of 57,200 H-shares, according to the Next Day Disclosure Return filed with the Hong Kong Stock Exchange.\n• Transaction details  \n– Price range: HKD 15.96 to HKD 16.70 per share  \n– Volume-weighted average price (Section I): HKD 16.51 per share  \n– Aggregate consideration: HKD 0.94 million\n• Impact on share capital  \n– Outstanding issued shares (excluding treasury) fell from 224.19 million to 224.13 million, a reduction of 0.0255%.  \n– Treasury share balance increased from 2.88 million to 2.94 million.  \n– Total issued shares (including treasury) remained unchanged at 227.07 million.\n• Repurchase mandate utilisation  \n– Shareholders approved a mandate on 29 May 2026 authorising repurchases of up to 22.44 million shares.  \n– Cumulative repurchases under the mandate now stand at 231,600 shares, representing 0.1032% of the company’s issued shares on the mandate date.  \n– A 30-day moratorium on new share issues or treasury share sales runs until 2 July 2026.\nThe company confirmed that all repurchases were conducted in accordance with Main Board Rule 10.06 and that no material changes have been made to the explanatory statement dated 8 May 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1123283149","isCrawlerRequest":true}